Gut health may hold key to preventing mania relapse
NCT ID NCT03383874
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether taking a daily probiotic supplement could prevent relapse in people recently hospitalized for mania. Over 24 weeks, 66 participants received either the probiotic or a placebo. The main goal was to see if the probiotic reduced the need for re-hospitalization. Researchers also tracked mood symptoms, thinking skills, and gut bacteria changes.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Probiotic supplement containing Lactobacillus rhamnosus and Bifidobacterium animalis subsp. lactis
- What this could lead to
- If it works, this could offer a simple, safe add-on treatment to help people with bipolar disorder stay stable after a manic episode.
- What could go wrong
- This is a small, early-stage trial with only 66 participants, so results may not apply to everyone. The effect may be small or not better than placebo.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 3
Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.
- Participants
-
67 people
The number who actually took part.
- Started
-
Sep 2018
- Finished
-
Sep 2024
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 65 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Capacity for written informed consent * Currently (or within the last 3 weeks) admitted to inpatient hospital for symptoms of mania. * Primary Axis I diagnosis (DSM-5) at time of admission of bipolar I (single manic episode, most recent episode manic, or most recent episode mixed) OR schizoaffective disorder, bipolar type (manic or mixed state). * Proficient in the English language. * Available to attend follow-up visits. Exclusion Criteria: * Substance- or medically-induced symptoms of mania at time of assessment. * HIV infection or other immunodeficiency condition (such as receiving cancer chemotherapy). * A serious medical condition that affects brain or cognitive functioning (e.g., epilepsy, serious head injury, concussion involving loss of consciousness, brain tumor, or other neurological disorder). Note that Hepatitis-C is not an exclusion criterion unless the participant has an acute infection. * Poorly controlled comorbid medical condition. * Major surgery in the last year. * History of weight loss surgery. * Diagnosis of Intellectual Disability or history of severe learning disorder. * Diagnosis of alcohol or substance use disorder (moderate/severe) according to DSM-5 criteria within the last 3 months, or has a positive drug toxicity screen proximate to the time of recruitment. * History of IV drug use. * Participated in any investigational drug trial in the past 30 days. * Abnormal electrolyte levels. * AST and ALT \> 3 times upper limit of normal. * Pregnant, breastfeeding, or planning to become pregnant during the study period. * Documented celiac disease (as such persons should be on a gluten-free diet as this is the standard care). Of note, we are not limiting the study to individuals with elevated levels of gliadin or casein antibodies as we intend to look at these levels as a predictor of response.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Bipolar I disorder are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Psychoneuroendocrine Research Program
Dallas, Texas, 75235, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a nasal insulin spray rev up brain energy and sharpen thinking in psychosis?
- Could immune cells hold clues to bipolar disorder?
- Can brain implants read and treat bipolar depression without triggering mania?
- Can a 10-Hour eating window stabilize mood in bipolar disorder?
- Gold nanoparticles may make lithium therapy safer and more effective
- Can a new drug calm the storm of bipolar mania?